Cobenfy (xanomeline-trospium) label expanded to include maintenance therapy for schizophrenia
FDA approved a supplemental label for Cobenfy (xanomeline and trospium chloride; Bristol Myers Squibb), the first muscarinic agonist for schizophrenia, to include a maintenance-of-effect indication. The update is supported by the EMERGENT-4 long-term extension trial demonstrating sustained symptom control and a favourable tolerability profile over 52 weeks without dopamine D2 blockade.
Cobenfy (xanomeline and trospium chloride; Bristol Myers Squibb) ↗ was originally approved by FDA in September 2024 as the first-in-class muscarinic cholinergic receptor agonist for schizophrenia. On 2 October 2026, FDA approved a supplemental application adding a maintenance-of-effect indication — demonstrating sustained symptom control and preventing relapse over 52 weeks in the EMERGENT-4 long-term extension trial.
Why this mechanism is novel
All prior approved antipsychotics act primarily via dopamine D2 receptor blockade ↗, which is linked to extrapyramidal side effects, tardive dyskinesia, and metabolic complications. Xanomeline is an M1/M4 muscarinic agonist that modulates dopamine and glutamate neurotransmission without direct D2 binding. Trospium, a quaternary ammonium muscarinic antagonist, is added to limit the peripheral cholinergic side effects of xanomeline without crossing the blood-brain barrier. The pharmacology is reviewed in the EMERGENT-2 trial paper in NEJM ↗.
EMERGENT-4 trial data
The EMERGENT-4 study was a 52-week open-label extension followed by a randomised withdrawal phase. Patients stabilised on Cobenfy were randomised to continue or switch to placebo. Time to relapse — measured by PANSS score worsening or hospitalisation — was significantly longer on Cobenfy vs placebo (p<0.001). Safety was consistent with earlier trials: nausea, dyspepsia, and constipation were the most common adverse events. Full protocol details are available at ClinicalTrials.gov NCT04738682 ↗.
Clinical context
Schizophrenia affects approximately 3.5 million Americans ↗ and remains a leading cause of disability. Up to 30% of patients are treatment-resistant to current D2 blockers. A non-dopaminergic option offers an alternative for patients who cannot tolerate existing agents or who experience inadequate symptom control. Prescribers can access current labelling on DailyMed ↗ and the Cobenfy HCP site ↗.
FAQ
What does FDA approval mean?
FDA approval means the agency has determined, based on scientific evidence submitted by the manufacturer, that a drug's benefits outweigh its known risks for a specific indication and patient population. The review process includes evaluation of clinical trial data, manufacturing quality, and proposed labelling. See the FDA drug approval process overview ↗.
Does approval mean the drug is available immediately?
Not always. Commercial launch timelines depend on manufacturing scale-up, pricing, and distribution. REMS-restricted drugs ↗ require prescriber or pharmacy enrolment before the product can be dispensed. Rare disease drugs may also have limited initial supply. Check the manufacturer's website or RxNav ↗ for availability status.